Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Role of Inhaled Nitric Oxide (iNO) on Pulmonary Hemodynamics in Patients with Intermediate/submassive and Massive Pulmonary Embolism (PE)

Next Previous
Trial Profile

Study to Evaluate the Role of Inhaled Nitric Oxide (iNO) on Pulmonary Hemodynamics in Patients with Intermediate/submassive and Massive Pulmonary Embolism (PE)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 05 Dec 2024 Planned End Date changed from 30 Jun 2023 to 30 Jun 2026.
  • 05 Dec 2024 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2025.
  • 05 Dec 2024 Planned initiation date changed from 1 Jun 2021 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top